Public drug policy for children in Canada

descriptionPublicationkeyboard_double_arrow_right Article 30 Jul 2017 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 189, pages E990-E994 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Avram E, Denburg; Wendy J, Ungar; Mark, Greenberg;

doi: 10.1503/cmaj.170380

pmid: 28760835

pmc: PMC5536988

Public drug policy for children in Canada

- Summary
- Subjects
- Metrics

Abstract

KEY POINTS Recent efforts have helped reform the global landscape of drug development to incorporate the unique needs of children into research and regulation.[1][1] However, an area of persistent inadequacy is public policy on funding for pediatric drugs, which varies widely by jurisdiction. Health

Related Organizations

Keywords

Canada, Technology Assessment, Biomedical, National Health Programs, Cost-Benefit Analysis, Health Policy, Humans, Child, Drug Approval

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%